133  0 Kommentare GLUCOTRACK ANNOUNCES ABSTRACTS ACCEPTED FOR POSTER PRESENTATION AT 84TH SCIENTIFIC SESSIONS OF THE AMERICAN DIABETES ASSOCIATION

The ADA Scientific Sessions is one of the premier diabetes conferences which provides a platform for the latest advancements in diabetes research, prevention, and care. This annual meeting provides researchers and health care professionals with the unique opportunity to share ideas and learn about cutting edge technologies and breakthroughs in diabetes research and diabetes-related conditions.

“We look forward to presenting two posters discussing the preclinical animal studies and the sensor longevity simulation modeling for our Continuous Blood Glucose Monitor (CBGM)” said Paul V. Goode, PhD, CEO of Glucotrack. “We are proud to pioneer new methods for continuous glucose monitoring which will enable it to be more automatic and less intrusive to daily living and we are excited to share our compelling data with clinicians, researchers and the diabetes community attending ADA.”

The posters will be made available on the Glucotrack website following the poster session at the conference. Presentation details are as follows; times noted are Eastern time:

Category: 13-B New Technology – Glucose Monitoring and Sensing
Session Date / Time: Saturday, June 22, 12:30 PM - 1:30 PM

Poster Number: 1010-P
Title: In Vivo Evaluation of Novel Long-Term Intravascular Implantable Continuous Blood Glucose Monitor in a Chronic Ovine Model – A Glucotrack Inc. Investigation

Lesen Sie auch

Ihre wichtigsten Termine

Alle Analysten-Augen auf: Biontech, Boeing, Zalando, Fresenius und Hensoldt AG

heute 04:30

Google, Meta abgestoßen

Hedgefonds-Star Tepper setzt auf China und spekuliert auf Rebound von Verlierern

gestern 12:30

Hedgefonds-Legende

Michael Burry trennt sich von Alphabet & Amazon – und wettet auf Alibaba & Gold!

gestern 10:29

Kurs bricht ein

Schott Pharma: Trübe Aussichten führen zu drastischem Kurseinbruch

15.05.24, 17:33

Poster Number: 1021-P
Title: In Silico Modeling of a Long-Term Implantable Continuous Blood Glucose Monitor: A Joint Investigation by Glucotrack Inc. and TTP

For more information about Glucotrack’s CBGM, visit glucotrack.com.

# # #

About GlucoTrack, Inc.

GlucoTrack, Inc. (NASDAQ: GCTK) is focused on the design, development, and commercialization of novel technologies for people with diabetes. The Company is currently developing a long-term implantable continuous blood glucose monitoring system for people living with diabetes.